Profile data is unavailable for this security.
About the company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
- Revenue in DKK (TTM)20.16bn
- Net income in DKK2.42bn
- Incorporated1950
- Employees5.70k
- LocationH Lundbeck A/SOttiliavej 9VALBY 2500DenmarkDNK
- Phone+45 36301311
- Fax+45 36301940
- Websitehttps://www.lundbeck.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AddLife AB | 6.30bn | 50.78m | 8.33bn | 2.29k | 169.67 | 2.60 | 12.73 | 1.32 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| BioGaia AB | 835.97m | 238.65m | 8.42bn | 211.00 | 36.64 | 6.27 | 33.11 | 10.08 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| BioArctic AB | 162.12m | -78.53m | 10.56bn | 90.00 | -- | 19.84 | -- | 65.13 | -1.38 | -1.38 | 2.86 | 11.24 | 0.2202 | -- | -- | 2,866,000.00 | -10.66 | 2.24 | -11.67 | 2.56 | 83.38 | 86.52 | -48.44 | 9.76 | -- | -- | 0.0043 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Bonesupport Holding AB | 421.53m | 171.35m | 10.60bn | 121.00 | 62.05 | 29.14 | 59.53 | 25.16 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 6.64bn | 984.37m | 13.53bn | 1.38k | 13.47 | 1.33 | 8.58 | 2.04 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Vitrolife AB | 2.25bn | -2.47bn | 16.16bn | 1.13k | -- | 1.90 | -- | 7.18 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Camurus AB | 1.17bn | 289.57m | 20.56bn | 218.00 | 71.25 | 12.09 | 68.79 | 17.55 | 7.79 | 7.79 | 31.75 | 45.91 | 0.8265 | 1.14 | 6.65 | 8,557,742.00 | 20.43 | -1.13 | 23.79 | -1.41 | 93.17 | 90.05 | 24.71 | -1.63 | 7.39 | -- | 0.0086 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 4.94bn | 555.00m | 31.38bn | 2.83k | 62.15 | 7.31 | 36.83 | 6.35 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| H. Lundbeck A/S | 20.16bn | 2.42bn | 36.56bn | 5.70k | 13.46 | 1.45 | 8.38 | 1.81 | 2.43 | 2.43 | 20.27 | 22.62 | 0.5413 | 0.9729 | 4.85 | 3,547,967.00 | 6.49 | 5.34 | 8.17 | 7.17 | 79.27 | 77.86 | 11.99 | 10.56 | 1.18 | 39.82 | 0.1565 | 31.72 | 9.13 | 1.91 | 19.52 | -10.13 | -6.58 | -- |
| Zealand Pharma A/S | 344.25m | -738.75m | 39.00bn | 270.00 | -- | 13.66 | -- | 113.29 | -12.52 | -12.52 | 5.78 | 45.56 | 0.1397 | 4.18 | 2.86 | 1,360,664.00 | -29.99 | -42.74 | -32.82 | -50.24 | 90.07 | 96.13 | -214.60 | -464.66 | 12.28 | -- | 0.1206 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Orion Oyj | 9.11bn | 1.62bn | 39.33bn | 3.70k | 24.11 | 7.41 | 19.96 | 4.32 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Swedish Orphan Biovitrum AB (publ) | 14.87bn | 1.38bn | 63.42bn | 1.75k | 44.98 | 2.64 | 17.76 | 4.26 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Genmab A/S | 17.76bn | 5.45bn | 132.39bn | 2.29k | 24.18 | 4.01 | -- | 7.45 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
Data as of May 22 2024. Currency figures normalised to H Lundbeck A/S's reporting currency: Danish Krone DKK
5.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 09 May 2024 | 3.90m | 1.96% |
| The Vanguard Group, Inc.as of 09 May 2024 | 1.93m | 0.97% |
| Nykredit Bank A/S (Investment Management)as of 31 Mar 2024 | 965.54k | 0.49% |
| Argenta Spaarbank NVas of 30 Jun 2023 | 907.13k | 0.46% |
| BlackRock Fund Advisorsas of 09 May 2024 | 805.74k | 0.41% |
| Handelsbanken Fonder ABas of 30 Apr 2024 | 689.30k | 0.35% |
| Bessemer Investment Management LLCas of 31 Jan 2024 | 422.17k | 0.21% |
| Danske Bank A/S (Investment Management)as of 29 Feb 2024 | 346.38k | 0.17% |
| Nordea Investment Management AB (Denmark)as of 31 Dec 2023 | 257.20k | 0.13% |
| Dimensional Fund Advisors Ltd.as of 09 May 2024 | 250.19k | 0.13% |
More ▼
Data from 31 Jan 2024 - 16 May 2024Source: FactSet Research Systems Inc.
